已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Simvastatin Addition to Standard of Care Improves Long-Term Survival in Patients With Cirrhosis After Variceal Bleed: An Open Label Randomized Controlled Trial

医学 辛伐他汀 自发性细菌性腹膜炎 肝硬化 内科学 胃肠病学 危险系数 失代偿 外科 置信区间
作者
Randeep Rana,Mohammad Tabish,Samagra Agarwal,Rajkumar Bayye,S. Ahmed,Deepak Gunjan,Sanchit Sharma,Anoop Saraya
出处
期刊:The American Journal of Gastroenterology [Lippincott Williams & Wilkins]
卷期号:121 (7): 1638-1649 被引量:3
标识
DOI:10.14309/ajg.0000000000003689
摘要

INTRODUCTION: There is limited evidence about efficacy and safety of simvastatin in decompensated cirrhosis. We assessed whether addition of simvastatin to standard of care improves long-term survival in patients with cirrhosis after variceal bleeding. METHODS: This was a single-center open label randomized controlled trial with superiority design. Patients with cirrhosis (Child-Pugh score 5-12) were randomly assigned to receive either simvastatin (20 mg once-daily) (n = 130) or no drug (n = 138) in addition to standard therapy (carvedilol and band ligation) at day 5 of variceal bleeding episode. Primary outcome was all-cause mortality over 24-month follow-up. Secondary outcomes included individual complications of cirrhosis with death before decompensation as a competing event. RESULTS: Baseline characteristics were similar in both groups with a mean age of 45.0 ± 11.5 years and alcohol (48%) being the predominant etiology. Most patients were of Child-Pugh A (34%) and B (50%) stage. Twenty-four patients (18%) on simvastatin and 44 (31%) on standard therapy died over follow-up (hazard ratio [HR] for simvastatin: 0.48 [95% confidence interval 0.29-0.81]; P = 0.006) with similar results on intention to treat and on per-protocol analysis (excluding 17 patients who stopped simvastatin). Incidence of ascites (subdistributional HR [sHR]) 0.60 (0.39-0.92) and spontaneous bacterial peritonitis (sHR 0.30 [0.11-0.81]) was lower in the simvastatin arm. All cause decompensation (sHR 0.74 [0.52-1.05]), rebleeding (sHR 0.87 [0.57-1.34]), hepatic encephalopathy (sHR 0.71 [0.42-1.19]), and acute-on-chronic liver failure (sHR 0.65 [0.39-1.10]) were comparable in both arms. No heterogeneity of treatment effect was demonstrated across Child-Turcotte-Pugh class ( P = 0.105) or etiology ( P = 0.39). Incidence of serious adverse events was similar (43% in simvastatin and 52% in standard therapy, absolute risk difference: 9.1% [-2.9% to 21.0%]). DISCUSSION: Simvastatin may be associated with improved survival in selected patients with cirrhosis after variceal bleed and reduced incidence of new onset/refractory ascites and its complications (CTRI/2022/07/044263).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
hjh发布了新的文献求助10
刚刚
熙熙攘攘发布了新的文献求助10
刚刚
任尔完成签到,获得积分20
2秒前
Sanction发布了新的文献求助10
3秒前
辞屿发布了新的文献求助10
3秒前
4秒前
5秒前
斯文败类的应助被ShaYdowzz采纳,获得10
5秒前
合适夜柳完成签到 ,获得积分10
6秒前
7秒前
8秒前
Maestro_S的应助被12345采纳,获得10
8秒前
机智的白卉的应助被jcx采纳,获得10
8秒前
9秒前
小小布丁丁完成签到 ,获得积分10
10秒前
李玉华关注了科研通微信公众号
10秒前
10秒前
10秒前
11秒前
11秒前
VDC的应助被我看看怎么个事采纳,获得30
11秒前
VDC的应助被我看看怎么个事采纳,获得30
11秒前
yh发布了新的文献求助10
12秒前
12秒前
小怪兽完成签到 ,获得积分10
14秒前
14秒前
16秒前
dochz发布了新的文献求助10
16秒前
17秒前
hyman发布了新的文献求助10
18秒前
20秒前
20秒前
上官若男的应助被热心的明辉采纳,获得10
21秒前
21秒前
俏皮以旋发布了新的文献求助10
22秒前
23秒前
科研通AI6.4的应助被Beto采纳,获得10
24秒前
25秒前
吉伊完成签到 ,获得积分10
25秒前
科研小白完成签到,获得积分10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184723
求助须知:如何正确求助?哪些是违规求助? 9573702
关于积分的说明 21832740
捐赠科研通 7782090
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558528
邀请新用户注册赠送积分活动 2481054